Gufic's margin recovery timeline has moved forward by two years
Indore break-even and a restructured critical care book have accelerated the path to 18% EBITDA in FY27, versus the FY29 timeline management gave investors last August.
What's new
- Q4 revenue ₹252 cr, up 23% YoY; EBITDA margin 17.7%, up 460 bps.
- Indore CMO hit 30% utilization and EBITDA break-even in Q4.
- FY27 guidance: 15% revenue growth, EBITDA margin ~18%, debt peaking at ₹400 cr.
- Canadian filler launch delayed from Jun-Jul 2026 to Q3-Q4 FY27.
Themes from the call
Margins
FY27 EBITDA guidance of ~18% is materially ahead of the FY29 recovery timeline management set in August 2025, driven by Indore break-even and a completed critical care working-capital reset.
Indore CMO
The facility reached 30% capacity and EBITDA break-even in Q4; at full utilization, management targets 21-22% EBITDA, which would lift consolidated margins toward 20%+ by 2030.
International model
Management is pivoting from distributor-led B2B supply to holding Marketing Authorizations directly via Gufic Ireland, a structural shift toward out-licensing and tech-fee revenue.
Guidance watch
- FY27 revenue growth guided at 15%, with EBITDA margin expanding to ~18% from FY26's 16.26%.
- Debt expected to peak at ₹400 cr and then hold range-bound.
- Consolidated EBITDA margin target: above 20% by 2030.
- New product launches to add ₹20-30 cr annually, net of tail-end discontinuations.
Risk flags
- Canadian filler launch slipped by several months without a stated reason. Management had previously cited Jun-Jul 2026 as the target.
- Critical care segment faces price erosion despite double-digit volume growth, capping upside.
- The two-year acceleration in margin recovery guidance invites scrutiny on what changed so quickly.
Key quotes
-
"Following the scale-up at Indore, I feel the EBITDA margin for FY27 should reach around 18%."
— Pranav Choksi, MD -
"I feel that EBITDA margin will going to come only after 2 years, not from not '26-'27 and '27-'28."
— Pranav Choksi, MD, Aug 2025 call
The brief
Gufic Biosciences' margin story has been rewritten in under a year. In August 2025, Pranav Choksi told investors EBITDA recovery was at least two years away, pinned to FY29. This quarter he guided FY27 EBITDA to ~18%, a sharp acceleration. The driver is Indore: the contract-manufacturing facility hit 30% utilization and EBITDA break-even in Q4, a critical gate. With 40 tech transfers complete and EU-GMP certification imminent, the facility's ramp is no longer a bet. It's a number.
The rest of the business is moving in sync. Q4 revenue hit ₹252 cr, the company's strongest quarter, up 23% year-on-year. EBITDA margin expanded 460 bps to 17.7%. The critical care vertical, which had dragged on working capital with 140-150 day hospital receivables, was restructured mid-year into a CFA-stockist model with a 30-45 day cycle. That reset cost ₹22 cr in revenue across quarters but is now complete.
The international pivot is the more structural play. Gufic Ireland now holds Marketing Authorizations directly, enabling revenue from direct supply, out-licencing, and tech-transfer fees. A major global health organization partnership unlocked procurement access across 109 countries. Revenue contribution from international sits at 18-19% today, with no incremental capex required.
The filler delay is a footnote, but it matters. Management targeted a June-July 2026 launch for the in-licensed Canadian product. It's now pushed to Q3-Q4 FY27. The gap wasn't explained. In a call where every other timeline accelerated, one slipped. That's worth watching.
Choksi's credibility here rests on execution. The FY27 guidance of 15% revenue growth and 18% EBITDA is credible only if Indore continues its ramp and the working-capital gains hold. The August 2025 caution has given way to confidence. The numbers support the turn. But guidance that moves this fast needs to hold just as firm.
Gufic's margin recovery arrived a year ahead of schedule. Now it has to stick.